These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26070946)

  • 1. A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.
    Steelandt J; Jean-Bart E; Goutelle S; Tod M
    Clin Pharmacokinet; 2015 Dec; 54(12):1245-58. PubMed ID: 26070946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
    Rasool MF; Khalil F; Läer S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
    Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
    Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Edginton AN; Willmann S
    Clin Pharmacokinet; 2008; 47(11):743-52. PubMed ID: 18840029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
    Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
    Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaling Factors for Clearance in Adult Liver Cirrhosis.
    El-Khateeb E; Achour B; Scotcher D; Al-Majdoub ZM; Athwal V; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2020 Dec; 48(12):1271-1282. PubMed ID: 32978222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin and magnetic resonance imaging-liver volume to identify hepatitis B-related cirrhosis and esophageal varices.
    Li H; Chen TW; Li ZL; Zhang XM; Li CJ; Chen XL; Chen GW; Hu JN; Ye YQ
    World J Gastroenterol; 2015 Jan; 21(3):988-96. PubMed ID: 25624735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
    Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
    J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A revised scope in different prognostic models in cirrhotic patients: Current and future perspectives, an Egyptian experience.
    Hassan EA; Abd El-Rehim AS
    Arab J Gastroenterol; 2013 Dec; 14(4):158-64. PubMed ID: 24433645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine.
    de Mey C; Mateva L; Krastev Z; Sachse R; Wood N; Malhotra B
    J Clin Pharmacol; 2011 Mar; 51(3):397-405. PubMed ID: 20371737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis.
    Huo TI; Wang YW; Yang YY; Lin HC; Lee PC; Hou MC; Lee FY; Lee SD
    Liver Int; 2007 May; 27(4):498-506. PubMed ID: 17403190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-to-abdominal area ratio for predicting the in-hospital mortality in advanced liver cirrhosis.
    Gao F; Wang R; Deng H; Hou F; Romeiro FG; Qi X
    Postgrad Med; 2017 Sep; 129(7):756-761. PubMed ID: 28486857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
    Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
    Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.